Houlihan Lokey Advises High Purity New England

Houlihan Lokey is pleased to announce that High Purity New England (HPNE) has been acquired by Getinge AB.

Getinge has acquired all outstanding shares from the shareholders of HPNE and paid approximately $120 million in cash on closing, on a cash-free and debt-free basis. In addition, a maximum earn out of approximately $170 million will be paid out in 2024–2026 if agreed net revenue performance milestones are achieved in 2023–2025. The acquisition was financed through cash on hand.

High Purity New England offers a comprehensive range of proprietary and distributed products from drug discovery and upstream and downstream processing to fill-and-finish. HPNE’s products assist leading biopharmaceutical and biotechnology players in the production of monoclonal antibodies, vaccines, cell and gene therapies, and other next-generation therapies. The company, founded in 2002, is a privately held company with approximately 150 employees. Its headquarters and production facilities are located in Smithfield, Rhode Island, in the United States.

Getinge is a global medical technology company that provides products and systems focused on enhancing quality and cost efficiency across the healthcare and life sciences industries. Getinge’s offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science. Getinge employs more than 10,000 people worldwide, and its products are sold in over 135 countries.

This transaction further strengthens and highlights Houlihan Lokey’s continued leadership in the medical technology industry. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the world. In 2022, the group closed 37 transactions and was ranked by Refinitiv as the No. 1 advisor for U.S. and global healthcare M&A transactions under $1 billion*.

Houlihan Lokey served as the exclusive financial advisor to High Purity New England and assisted in initiating, structuring, and negotiating the transaction on its behalf.

*Excludes accounting firms and brokers.